论文部分内容阅读
本文总结31例儿童急性非淋巴细胞白血病(AML)的疗效:M_3组13例,均予全反式维甲酸(ATRA)诱导分化缓解,再予ATRA及化疗交替维持强化治疗。其它AML组18例给联合化学治疗。结果:完全缓解96.8%,持续完全缓解50%,临床治愈10%。复发40%。我们认为坚持长期、正规治疗,可提高无病生存率。运用分子生物学检测,可为临床选择治疗方案,判断预后及终止治疗提供依据。
This article summarizes the results of 31 children with acute non-lymphocytic leukemia (AML): M_3 group of 13 patients were induced differentiation of all-trans retinoic acid (ATRA), and then ATRA and chemotherapy to maintain intensive treatment. Other AML group of 18 cases to the combined chemotherapy. Results: Complete remission 96.8%, sustained and complete remission 50%, clinical cure 10%. Recurrence 40%. We believe that upholding long-term and formal treatment can increase the rate of disease-free survival. The use of molecular biology tests for clinical choice of treatment options to determine the prognosis and termination of treatment provide the basis.